MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Verona Pharma VRNA has signed a definitive agreement with pharma bigwig Merck MRK. Per the terms, the pharma giant will ...

Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - ...

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

CD8⁺ T cells are the immune system's frontline warriors, charged with detecting and eliminating cancer cells. But in the hostile and chronic environment of tumors, these cells often falter.

The story behind the development of immune checkpoint inhibitors, fulfilling the promise of cancer immunotherapy ...